RB Capital Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.81M | Buy |
15,124
+208
| +1% | +$44.8K | 0.74% | 33 |
|
|
2026
Q1 | $3.24M | Buy |
14,916
+183
| +1% | +$40.6K | 0.69% | 36 |
|
|
2025
Q4 | $3.37M | Buy |
14,733
+104
| +0.7% | +$23.7K | 0.67% | 36 |
|
|
2025
Q3 | $3.39M | Buy |
14,629
+376
| +3% | +$76.6K | 0.7% | 36 |
|
|
2025
Q2 | $2.65M | Buy |
14,253
+192
| +1% | +$35.7K | 0.6% | 41 |
|
|
2025
Q1 | $2.95M | Buy |
14,061
+192
| +1% | +$37.3K | 0.68% | 35 |
|
|
2024
Q4 | $2.46M | Sell |
13,869
-270
| -2% | -$49.6K | 0.56% | 44 |
|
|
2024
Q3 | $2.79M | Buy |
14,139
+26
| +0.2% | +$4.85K | 0.65% | 38 |
|
|
2024
Q2 | $2.42M | Buy |
14,113
+62
| +0.4% | +$10.3K | 0.6% | 43 |
|
|
2024
Q1 | $2.56M | Buy |
14,051
+610
| +5% | +$105K | 0.67% | 37 |
|
|
2023
Q4 | $2.08M | Sell |
13,441
-273
| -2% | -$39.8K | 0.6% | 41 |
|
|
2023
Q3 | $2.04M | Buy |
13,714
+425
| +3% | +$62.4K | 0.64% | 40 |
|
|
2023
Q2 | $1.79M | Buy |
13,289
+474
| +4% | +$69.5K | 0.54% | 44 |
|
|
2023
Q1 | $2.04M | Buy |
12,815
+669
| +6% | +$102K | 0.65% | 41 |
|
|
2022
Q4 | $1.96M | Buy |
12,146
+426
| +4% | +$65.3K | 0.69% | 38 |
|
|
2022
Q3 | $1.57M | Buy |
11,720
+1,536
| +15% | +$220K | 0.6% | 40 |
|
|
2022
Q2 | $1.56M | Buy |
10,184
+1,069
| +12% | +$163K | 0.58% | 45 |
|
|
2022
Q1 | $1.48M | Buy |
9,115
+273
| +3% | +$39.7K | 0.47% | 50 |
|
|
2021
Q4 | $1.2M | Buy |
8,842
+493
| +6% | +$58.2K | 0.37% | 58 |
|
|
2021
Q3 | $901K | Buy |
8,349
+750
| +10% | +$85.7K | 0.34% | 69 |
|
|
2021
Q2 | $856K | Sell |
7,599
-30
| -0.4% | -$3.38K | 0.32% | 72 |
|
|
2021
Q1 | $826K | Sell |
7,629
-898
| -11% | -$96.1K | 0.36% | 65 |
|
|
2020
Q4 | $914K | Buy |
8,527
+2,416
| +40% | +$232K | 0.42% | 53 |
|
|
2020
Q3 | $537K | Sell |
6,111
-342
| -5% | -$32.2K | 0.25% | 80 |
|
|
2020
Q2 | $633K | Buy |
6,453
+28
| +0.4% | +$2.46K | 0.34% | 70 |
|
|
2020
Q1 | $483K | Sell |
6,425
-137
| -2% | -$11.7K | 0.31% | 75 |
|
|
2019
Q4 | $582K | Sell |
6,562
-125
| -2% | -$10.4K | 0.33% | 72 |
|
|
2019
Q3 | $498K | Buy |
6,687
+780
| +13% | +$53.5K | 0.32% | 75 |
|
|
2019
Q2 | $429K | Buy |
5,907
+196
| +3% | +$15.4K | 0.31% | 76 |
|
|
2019
Q1 | $461K | Buy |
5,711
+376
| +7% | +$30.8K | 0.38% | 65 |
|
|
2018
Q4 | $492K | Buy |
5,335
+106
| +2% | +$9.32K | 0.5% | 55 |
|
|
2018
Q3 | $495K | Sell |
5,229
-886
| -14% | -$84K | 0.44% | 63 |
|
|
2018
Q2 | $567K | Buy |
6,115
+941
| +18% | +$91.9K | 0.42% | 61 |
|
|
2018
Q1 | $490K | Buy |
5,174
+107
| +2% | +$11.8K | 0.39% | 67 |
|
|
2017
Q4 | $490K | Buy |
5,067
+128
| +3% | +$12.1K | 0.35% | 68 |
|
|
2017
Q3 | $439 | Sell |
4,939
-375
| -7% | -$28.5K | 0.01% | 67 |
|
|
2017
Q2 | $385K | Sell |
5,314
-123
| -2% | -$8.27K | 0.33% | 69 |
|
|
2017
Q1 | $354K | Buy |
5,437
+663
| +14% | +$41.7K | 0.34% | 74 |
|
|
2016
Q4 | $299K | Buy |
+4,774
| New | +$291K | 0.3% | 82 |
|
Other funds holding ABBV
RB Capital Management's ABBV Position: Q2 2026 in Review
RB Capital Management increased its AbbVie (ABBV) stake by 1.4% in Q2 2026, buying an estimated $44.8K and bringing the position to 15,124 shares worth $3.81M. The position accounts for 0.74% of the portfolio, ranked #33.
RB Capital Management first reported a position in ABBV in Q4 2016 and has held it in 39 quarters since. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- RB Capital Management held 15,124 shares of AbbVie worth $3.81M as of Q2 2026.
- RB Capital Management bought 208 AbbVie shares in Q2 2026, an estimated $44.8K.
- AbbVie made up 0.74% of RB Capital Management's portfolio in Q2 2026, its #33 holding.
- RB Capital Management first reported a position in AbbVie in Q4 2016 and has held it in 39 quarters since.
- 4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on RB Capital Management's 13F filing for Q2 2026, filed 18 Aug 2026.